Por lo Qué Hasta la Obtención de los Resultados Completos ... Más la Elaboración del Dossier ... Más la Evaluación de las Agencias ... Nos Podemos Ir al 2027 .
06 noviembre 2013
Mona Lisa por el Cáncer . " Un tumor cambia la vida. No su valor ".
*.- Una ONG Italiana utiliza a la Dama de Leonardo Da Vinci para concienciar sobre el Cáncer .
*.- La Campaña quiere destacar la Dignidad de los Pacientes a pesar de los Cambios Físicos .
...
Yondelis® (trabectedin) in the spotlight at the 18th Annual Meeting of the Connective Tissue Oncology Society (CTOS) with twenty-one trials .
ZELTIA NEWS:
A selection of recent trials with trabectedin (Yondelis®), the marine-based drug developed by PharmaMar, the Grupo Zeltia (MC:ZEL) biotechnology subsidiary, was the central focus of the scientific programme at one of the leading international oncology events
The combination of trabectedin+doxorubicin offers significant clinical benefits in patients with metastatic uterine leiomyosarcoma and soft tissue leiomyosarcoma, with an acceptable safety profile
Trabectedin can be considered as an option for first-line treatment in translocation-related sarcomas.
...
A selection of recent trials with trabectedin (Yondelis®), the marine-based drug developed by PharmaMar, the Grupo Zeltia (MC:ZEL) biotechnology subsidiary, was the central focus of the scientific programme at one of the leading international oncology events
The combination of trabectedin+doxorubicin offers significant clinical benefits in patients with metastatic uterine leiomyosarcoma and soft tissue leiomyosarcoma, with an acceptable safety profile
Trabectedin can be considered as an option for first-line treatment in translocation-related sarcomas.
...
Suscribirse a:
Entradas (Atom)